Gossamer Bio, Inc. (FRA:4GB)

Market Cap	418.46M +67.3%
Revenue (ttm)	37.54M -58.2%
Net Income	-133.10M
EPS	-0.59
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,305
Open	1.742
Previous Close	1.828
Day's Range	1.740 - 1.771
52-Week Range	0.648 - 3.174
Beta	n/a
RSI	37.15
Earnings Date	Mar 11, 2026

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 145
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4GB

Financial Performance

Financial numbers in USD